Cowen Sees Favorable Risk/Reward in Endocyte (ECYT) Amid Phase III Trial of PSMA-617
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Endocyte (ECYT) Prices 17.86M Share Common Offering at $4.20/Sh
February 28, 2018 9:20 AM ESTEndocyte, Inc. (NASDAQ: ECYT) announced today the pricing of an underwritten registered public offering of 17,857,143 shares of its common stock at a price to the public of $4.20 per share. In addition, Endocyte granted the underwriters a 30-day option to purchase up to an... More
UPDATE: Cowen Upgrades Endocyte (ECYT) to Outperform Citing 'Very Favorable' Risk/Reward at Current Valuation
February 27, 2018 5:33 AM EST(Updated - February 27, 2018 7:36 AM EST)
(updated to add analyst comments)
Cowen upgraded Endocyte (NASDAQ: ECYT) from Market Perform to Outperform.
Analyst Boris Peaker commented, "We are upgrading ECYT from Market Perform to Outperform without a price target. The company... More
Endocyte (ECYT) Reports Supply Agreement with ITM for EndolucinBeta in Phase 3 VISION Trial
February 26, 2018 11:47 AM ESTEndocyte, Inc. (NASDAQ Global Market: ECYT), and ITM... More
Endocyte (ECYT) Reports Update on Phase 3 VISION Trial
February 26, 2018 8:05 AM ESTEndocyte, Inc. (NASDAQ: ECYT) today provided an update on its corporate strategy and announced financial results for the fourth quarter and full year ending Dec. 31, 2017.
Following a successful End of Phase 2 meeting with the FDA, we are excited to launch the VISION trial, a phase 3 registration trial of 177Lu-PSMA-617 in patients with prostate cancer, said Mike Sherman, president and CEO of Endocyte. After extensive collaboration with prostate cancer specialists around the world, the robust and sophisticated VISION trial design will be attractive to patients and physicians when we begin enrollment in the second... More
